How to utilize the DDR, DNA Damage Response mechanism to inhibit the growth of tumor cells, especially overcoming drug resistance, has been a hot topic in pharmaceutical research over the past decade. Targeting DDR pathways, we have introduced a DDR cell panel that covers 10 cancer types, totaling 80 tumor cell lines, including common tumor cell lines, gene-edited cells such as BRCA-KO, and drug-resistant cell lines. This panel can be used for screening the activity and selectivity of DDR-related inhibitors. Due to the slow-acting nature of DDR-targeting drugs, we are offering assays with a duration of 7-14 days.

ICE Bioscience has developed a series of engineered cell lines for Ba/F3-EGFR mutations. We have introduced a cell panel targeting the EGFR receptor, which includes 70 Ba/F3 cell lines with both wild-type and mutant EGFR, available for testing the activity and selectivity of EGFR inhibitors. Additionally, we can provide assays for tumor cell lines with natural EGFR mutations and resistant cell lines based on researchers' needs.

For the KRAS target, ICE Bioscience has developed a series of engineered cell lines, including Ba/F3-KRAS mutant cells. As natural tumor cell lines also exhibit numerous KRAS mutations, we are introducing a cell panel specific to the KRAS target. This panel consists of 30 Ba/F3-KRAS mutant cell lines and 30 KRAS mutant tumor cell lines, totaling 60 cell lines. It can be utilized for the assessment of the activity and selectivity of KRAS inhibitors.

Targeted HER2 ADCs have emerged as a highly promising approach for treating HER2-positive cancers. To facilitate the development of HER2-targeted ADC drugs, ICE team has established a cell panel comprising 65 cell lines. This panel includes 53 tumor cell lines with varying levels of HER2 expression and 12 engineered Ba/F3 cell lines with HER2 mutations. We provide this specilized cell panel for the research and development of HER2-targeted ADC drugs.